| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | 0.025 | 0.7 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |